SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription

BACKGROUND: ChAdOx1 nCoV-19 is a recombinant adenovirus vaccine against SARS-CoV-2 that has passed phase III clinical trials and is now in use across the globe. Although replication-defective in normal cells, 28 kbp of adenovirus genes is delivered to the cell nucleus alongside the SARS-CoV-2 S glyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Almuqrin, Abdulaziz, Davidson, Andrew D., Williamson, Maia Kavanagh, Lewis, Philip A., Heesom, Kate J., Morris, Susan, Gilbert, Sarah C., Matthews, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958140/
https://www.ncbi.nlm.nih.gov/pubmed/33722288
http://dx.doi.org/10.1186/s13073-021-00859-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958140/
https://www.ncbi.nlm.nih.gov/pubmed/33722288
http://dx.doi.org/10.1186/s13073-021-00859-1

Ejemplares similares